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study question: What are the effects of dienogest (DNG) on midkine (MK) production in women with endometriosis?
summaryanswer: DNG-mediated down-regulation of MK in vivo and in vitro.
what is known already: DNG is an oral progestin that alleviates painful symptoms of women with endometriosis with a favourable
tolerability and safety proﬁle. Its effects on MK, a growth factor that plays an important role in endometriosis, have not yet been investigated.
study design, size, duration: Prospective in vivo study on 283 patients subjected to laparoscopy for benign pathologies in a Uni-
versity hospital and in vitro culturesof primaryendometrial stromal cells (ESC) from6of thesewomenwith histologically conﬁrmedendometriosis.
participants/materials, setting, methods: MK concentrations in the peritoneal ﬂuid (PF) of women were measured by
ELISA and compared based on endometriosis status and the use of DNG. A subsequent in vitro analysis with ESC was used to conﬁrm the
direct inﬂuence of DNG and other progestins including, norethisterone acetate (NETA) and medroxyprogesterone acetate (MPA) on MK
mRNA production.
main results and the role of chance: The ﬁnal study population consisted of 253women.Of these, 165 suffered fromendomet-
riosis, with 62 of them taking DNG (DNG group) and 103 taking no hormone treatment (non-DNG group) during at least 3 months before surgery.
Another 88 women were endometriosis free (non-endometriosis group). The concentration of MK was highest in the PF of women in the non-DNG
group (median 5.26 ng/ml, IQR 2.74–8.46). Signiﬁcantly lower concentrations were found in the non-endometriosis group (median 3.51 ng/ml, IQR:
1.90–7.53, P¼ 0.028). The lowest concentrationswere found in theDNGgroup (median2.44 ng/ml, IQR: 1.12–4.70, P, 0.0001 versus non-DNG
group, P¼ 0.048 versus non-endometriosis group). The treatment of primary cultured ESCwith DNG (1025 M) suppressed MKmRNA production
(P ¼ 0.016), whereas MPA (P ¼ 0.109) and NETA (P ¼ 0.422) at same concentrations did not show a similar effect.
limitations, reasons for caution: The non-randomized design of the study.
wider implications of the findings: These ﬁndings could indicate a direct effect ofDNGonendometriotic cells that could contrib-
ute to its effectiveness in the treatment of this disease.
study funding/competing interest(s): Funding was received from Swiss National Science Foundation (Grant No.
320030_140774).M.D.M. has received fees for speaking at scientiﬁcmeetings fromBayer. Theother authors have no conﬂicts of interest todeclare.
The authors state that the manufacturer of dienogest has in no way inﬂuenced the performance or outcomes of this study.
Key words: endometriosis / midkine / growth factors / cytokines / dienogest / norethisterone acetate / norethindrone acetate /
medroxyprogesterone acetate
Introduction
Endometriosis is a prevalent gynecological disorder affecting at least
10% of reproductive-aged women worldwide (Eskenazi and Warner,
1997). It is characterized by the growth of endometrial epithelial and
stromal cells outside the uterine cavity and can result in severe pelvic
pain and subfertility. In addition, it is increasingly being recognized as
an inﬂammatory disease with elevated concentrations of growth
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factors and cytokines in the peritoneal ﬂuid (PF) of women with endo-
metriosis compared with women without (Koga et al., 2000; Osuga
et al., 2000; Yoshino et al., 2003; Bersinger et al., 2006). Local inﬂamma-
tory and immunological phenomena (Sturlese et al., 2011;Kra´lı´cˇkova´ and
Vetvicka, 2015; Salmeri et al., 2015; Lagana` et al., 2016) create this
altered peritoneal microenvironment that facilitates the pathogenesis
of endometriosis and may explain why some women experience more
severe symptoms than others (McKinnon et al., 2015).
Midkine (MK) is a low-molecular weight non-glycosylated protein also
known as neurite growth-promoting factor-2. It is highly expressed
during the midgestation stage of embryogenesis, but is restricted to a
limited number of tissue in adults (Muramatsu, 2011). There is also a
strong induction of MK during oncogenesis, inﬂammation and tissue
repair (Muramatsu, 2002)makingMKaprotein of interest in disease pro-
gression and pharmaceutical targeting. MKmay contribute to the patho-
genesis of endometriosis through the stimulation of cell proliferation,
migration, angiogenesis and ﬁbrinolysis (Muramatsu, 2010), as well as
to neuronal growth (Winkler and Yao, 2014). Higher expression of
MK in the endometrium of women with endometriosis compared with
women without has been conﬁrmed (Chung et al., 2002). PF concentra-
tions ofMK are higher inwomenwith advanced stages of the disease and
MK stimulates the proliferation of cultured endometrial stromal cells
(ESC; Hirota et al., 2005).
The suppression of MK by gonadotrophin-releasing hormone analo-
gues (GnRHa), which have been used as a ﬁrst line treatment for
endometriosis-related pain may be an important facet in the efﬁcacy of
these drugs (Hirota et al., 2005; Nirgianakis et al., 2013). More recently,
however, dienogest (DNG), a synthetic progestin, has been introduced
for the treatment of endometriosis providing similar efﬁcacy, but better
tolerability than GnRHa (Cosson et al., 2002; Strowitzki et al., 2010).
Whether DNG also inﬂuences MK concentrations has not yet been
investigated, although direct anti-proliferative and anti-inﬂammatory
effects have been observed on endometriotic stromal cells (Horie
et al., 2005; Fu et al., 2008; McCormack, 2010; Grandi et al., 2016).
In the present study, we therefore wished to further examine the
effects of DNG through investigating its impact on MK production. To
do this, we evaluated the inﬂuence of DNG on MK PF concentrations
and performed subsequent in vitro experiments to determine if the inﬂu-
ence of DNG occurs directly on endometrial tissue.
Materials andMethods
Patient selection and collection of PF samples
This study was prepared according to the ‘Strengthening the Reporting of
Observational studies in Epidemiology’ guidelines (von Elm et al., 2007).
Women undergoing laparoscopic surgery for benign pathologies in the De-
partment of Obstetrics and Gynaecology, University of Berne (Switzerland)
between June 2011 andOctober 2015 were included in the study. Exclusion
criteria were the use of hormonal drugs other than DNG 2 mg daily
(Visannew, Bayer Healthcare, Leverkusen, Germany) in the 3 months prior
tosurgery, patients suffering fromother inﬂammatorydiseases, pregnancy,ma-
lignancy and surgery performed in an emergency situation. Written informed
consent and detailed information on hormonal treatment usage was obtained
from all participants prior to surgery, and the project was approved by the
relevant Ethical committee. All procedures were performed during the prolif-
erativephaseof themenstrual cycle, conﬁrmedbythemeasurementofproges-
terone in the PF with a cut-off value of 10 nmol/l. Intraoperative ﬁndings and
revised American Fertility Society stage of endometriosis were documented
(rAFS, 1997).
Eutopic endometrium was obtained via endometrial Pipellew (Pipelle
deCornier, Laboratoire CCD, Paris, France) biopsies and the PF collected
from the cul-de-sac at the beginning of the laparoscopy before any other sur-
gical procedure had been performed. The endometrial biopsies were trans-
ferred to culture medium containing fetal calf serum (10%, v/v) and DMSO
(10–20%, v/v), slow-frozen to 2808C in a Bicellw chamber and stored in
liquid nitrogen for later use. PF samples were clariﬁed by centrifugation
(10 min at 1800× g) and stored undiluted in 0.5–1.0-ml aliquots at
2708Cprior to assay. Cases with haemolysed PF supernatants or insufﬁcient
PF volume were excluded, as described previously (McKinnon et al., 2014).
For comparison of MK concentrations, patients were split into three
groups: (i) patients with endometriosis receiving DNG prior to surgery
(DNG group), (ii) patients with endometriosis but no hormonal treatment
prior to surgery (non-DNG group) and (iii) patients without endometriosis
(non-endometriosis group).
MKmeasurement in PF
The total protein concentration in the PF samples was determined with
the micro-bicinchoninic acid method (Quanti-Prow BCA, Sigma-Aldrich,
St. Louis, MO, USA; Nisolle et al., 1994). MK concentrations were deter-
mined by microplate ELISA as described in the previous reports from our
laboratory (Bersinger et al., 2006; Scholl et al., 2009). At the time of these
measurements the laboratory had no knowledge of the presence or the
absence of endometriosis or of DNG treatment.
Isolation and culture of primary ESC
Primary ESC were isolated from endometrial biopsies from six different
women with histologically conﬁrmed endometriosis and no hormonal ther-
apies within the previous 3 months, using methods described previously
(McKinnon et al., 2014). Brieﬂy, separationwasperformed via collagenase di-
gestion (Collagenase from Clostridium histolyticum, Sigma Life Sciences, MO,
USA) and size exclusion membranes (100 and 40 mm mesh ﬁlters, BD Bio-
science, NJ, USA). Isolated ESC were maintained in Iscoves’s modiﬁed
Eagle medium (IMEM) (Invitrogen Life Technologies, NY, USA) supplemen-
tedwith 10% (v/v) fetal calf serum (FCS) and1% (v/v) antibiotic/antimycotic
(Invitrogen Life Technologies) at 378C in a humidiﬁed atmosphere. CO2was
added to the normal atmospheric conditions. The culture medium was
changed every 3 days.
In the experiments cells were seeded onto 6-well plates and grown until
80% conﬂuence. Prior to treatments the FCS concentration in the
medium was changed to 0.5% (v/v). In vitro treatments were performed
for 6 h with medroxyprogesterone acetate (MPA; Sigma-Aldrich), norethis-
terone acetate (NETA; Sigma-Aldrich) and DNG (Bayer HealthCare, Lever-
kusen,Germany), all at a concentration of 1025 M.After incubation, the cells
were collected in RNA lysis buffer (Qiazolw Lysis Reagent, Qiagen, MD,
USA).
Analysis of MK gene expression
RNA extraction was performed with the RNAeasyw Plus Micro extraction Kit
(Qiagen) following the manufacturer’s instructions. One microgram of RNA
was reverse transcribed to cDNA in a ﬁnal volume of 25 ml with the Moloney
Murine leukaemia virus Reverse transcriptase enzyme and random primers
(Promega, Madison, WI, USA) and diluted 1:20. Genomic DNA absence was
conﬁrmed via a no-enzymeRT control (RT-). Gene expressionwas determined
by Real-time quantitative Polymerase chain reaction (qPCR) using Rotor-gene
Taqman Fast advanced Master Mix (Qiagen) and the following TaqManw gene
expression primer/probes for MK gene (Hs00171064_m1) and reference
genes hypoxanthine phosphoribosyltransferase-1 (HPRT1; Hs01003267_m1),
beta-actin (Hs01060665_g1), ubiquitin C (Hs00824723_m1), glyceraldehyde
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3-phosphate dehydrogenase (GAPDH; Hs00266705_g1) and ribosomal
proteinL13A(RPL13A;Hs04194366_g1).TheqPCRwasperformed inaRotor-
GeneRG2000 (Corbett Research,NewSouthWales,Australia), under the fol-
lowing conditions: 958C for 5 min, followed by 40 cycles consisting of 958C for
5 s and 608C for 10 s.
Reference genes were selected with the qBASE software suite based on
their stability across samples (Biogazelle, Ghent University, Belgium) and
the change in mRNA expression for MK calculated via the qBASE software,
based on the geometric mean of the multiple reference genes and theDDCt
method. The efﬁciency of each reaction, as determined via linear regression
(Kato et al., 2000) was also incorporated into the equation. All RNA quan-
tities are expressed as percentages of control.
Statistical analysis
Median values and interquartile range (IQR) or mean and standard deviation
were calculated for continuous variables as appropriate and percentages for
the qualitative variables. Statistical analysis for the comparisonofMKconcen-
trations between groups was done by Mann–Whitney U test, while for MK
mRNA production a non-parametric Wilcoxon matched paired test was
used. Other parameters (age, BMI, protein concentration, volume of aspi-
rated PF) were compared between groups by x2 or ANOVA as appropriate.
Graph-Pad Prism version 3.03 was used, and the signiﬁcance was set at a
P value of ,0.05.
Results
Atotal of 283patientswere included in the study. In 30patients itwasnot
possible to measure the PF MK concentration due either to a dilution of
the ﬂuid under the surgical procedure (detected by the aspect and a low
total protein concentration) or to the presence of haemolysis; these
cases were thus excluded from the statistical analysis. In the remaining
253 patients, 165 (65.2%) were diagnosed with endometriosis, with 62
(24.5%) using DNG (DNG group) and 103 (40.7%) using no hormonal
treatments (non-DNG group). The remaining 88 (34.8%) patients
were conﬁrmed endometriosis free and were not taking any hormonal
treatments prior to surgery (non-endometriosis group). A comparison
between groups showed that the stage of endometriosis, as measured
by the revised American Fertility Society (rAFS) staging system, was
signiﬁcantly higher in the DNG than in the non-DNG group (P ¼
0.0405). Patient characteristics and PF concentrations are shown in
Table I.
MK concentrations in PF
MKconcentrations in thePFofwomenwith endometriosiswerehighest in
the non-treated endometriosis (non-DNG) group (median 5.26, IQR
2.74–8.46 ng/ml). Compared with that, MK concentrations were signiﬁ-
cantly lower in both the non-endometriosis group (median 3.51, IQR:
1.90–7.53 ng/ml, P ¼ 0.0275) and the DNG-treated endometriosis
group (median 2.44, IQR: 1.12–4.70 ng/ml, P, 0.0001).MK concentra-
tions in the DNG-treated endometriosis group were even signiﬁcantly
lower than in the group without endometriosis (P ¼ 0.0483) (Fig. 1).
Inhibition of MKmRNA production
A signiﬁcant reduction in MK mRNA production when compared with
control (100%) was observed after treatment with 1025 M DNG
(36.31+ 25.20%, P ¼ 0.016) (Fig. 2A). In contrast, a non-signiﬁcant in-
crease in MK expression was observed after treatment with 1025 M
MPA (172.40+115.00%, P ¼ 0.109) (Fig. 2B) and 1025 NETA
(180.80+168%, P ¼ 0.422) (Fig. 2C).
Discussion
In thepresent study,wewereable todemonstrate thatDNGsuppressed
MK concentrations in the PF of women with endometriosis. Moreover,
MK levels were lower in women with endometriosis under DNG even
though they presented with a higher rAFS stage than women without
DNG. This inﬂuence was conﬁrmed in an in vitro treatment of primary
ESC from endometriotic women at the mRNA level and it was speciﬁc
to DNG as other progestins used for the treatment of endometriosis
failed to produce a similar effect.
MK is a potent proliferative and neurogenic mediator that enhances
the angiogenic and proliferative activities of cancer cells (Kato et al.,
2000). The expression of MK is elevated in multiple cancers, such as
neuroblastoma, glioblastoma, Wilms’ tumours, thyroid papillary
.......................................................
.............................................................................................................................................................................................
Table I Patient characteristics in the three groups of patients included.
Endometriosis Non-endometriosis group P Value
DNG group Non-DNG group
Number of women 62 103 88
Age (years) 31.1+5.7 34.4+5.9 36.4+7.9 <0.0001a
Body mass index (kg/m2) 22.9+3.4 23.5+4.4 24.4+4.1 0.0700a
rAFS stage I 15 (24) 32 (31) n/a 0.0405b
rAFS stage II 6 (10) 17 (17) n/a
rAFS stage III 8 (13) 22 (21) n/a
rAFS stage IV 33 (53) 32 (31) n/a
PF collected (ml) 8.8+8.2 10.7+9.0 8.7+6.6 0.1586a
Protein concentration in PF (mg/ml) 38.0+12.1 33.5+14.5 35.8+12.1 0.0991a
Data are presented as n (%), or mean+ SD. Signiﬁcant P-values are marked bold.
DNG, dienogest; rAFS, revised American Fertility Society; PF, peritoneal ﬂuid.
aStatistical analysis performed by one-way ANOVA.
bStatistical analysis performed by x2 in a 2 × 4 contingency table.
Dienogest and midkine in endometriosis 1983
 at E-Library Insel on January 26, 2017
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
carcinomas, colorectal, liver, ovary, bladder, breast, lung, oesophageal,
stomach and prostate cancers (Ikematsu et al., 2000). It has also been
found elevated in the PF of women with endometriosis (Chung et al.,
2002; Hirota et al., 2005), a result we were able to conﬁrm. In contrast,
its expression in normal adult tissue is limited. Such an increase in benign
and malignant tumours suggests an important role for MK in the patho-
genesis of these conditions. MK has also been shown to activate the
AKT/mTOR pathway leading to increased cellular proliferation and
cell resistance to chemotherapeutics (Mirkin et al., 2005) and this
kinase signalling pathway may play an important role in endometriosis
(McKinnon et al., 2016). Moreover, as a neurite growth-promoting
factor, MK could be an important molecule for peripheral nerve stimula-
tion and sensitization in endometriosis, as described recently (McKinnon
et al., 2015). Finally, several studies have focused on the possible
dissemination of primordial endometrial stem cells in ectopic regions
during the organogenesis and differentiation of Mu¨llerian structures of
the female reproductive tract (Lagana` et al, 2013; Kobayashi et al.,
2014). This could predispose to endometriosis in these regions later in
life. Since MK is widely produced during the midgestation stage of em-
bryogenesis it could be possible that it is implicated in this process.
The roleofMK in pathogenesis and thus the local inﬂuenceofDNGon
endometriotic lesion growth and symptomatology is not answered by
this study, although it deserves further attention. If the importance of
MK in the establishment and development of endometriosis can be con-
ﬁrmed it may be interesting to explore the therapeutic potential of MK
inhibitors, either in combination with progestins or alone, in the treat-
ment of endometriosis.
At present only two progestins, NETA and MPA (Quaas et al, 2015),
have been approved by the US Food and Drug Administration (http
://www.fda.gov/Drugs) for the treatment of endometriosis. A third
progestin, DNG, has received approval as a monotherapy for the treat-
ment of endometriosis in Europe, Japan, Australia and Singapore
(Dunselman et al., 2014). Amongst these three progestins, only DNG
decreased MK mRNA production by ESC in our in vitro study implying
multiple mechanisms of action at the transcriptional level may exist for
the different progestins.
Previous evidence supports a similar progesterone receptor
(PR)-mediated activity of DNG and other progestins on protein produc-
tion and secretion in ESC fromwomenwith endometriosis (Okada et al.,
2001; Horie et al., 2005; McCormack, 2010; Grandi et al., 2016). Para-
doxically, however, ESC from women with endometriosis are consid-
ered progesterone resistant due to a signiﬁcant down-regulation of the
PR (Bulun et al., 2010). Furthermore, the different progestins have
varied afﬁnities to other nuclear receptors, including the glucocorticoid,
mineralocorticoid and androgen receptors that also stimulate gene tran-
scription. A combination of the suppressed PR expression and various
afﬁnities for other nuclear receptors therefore could lead to variations
in the transcriptional activities of these medications.
The in vitro effect of DNGon stromal cells could partially explain the in
vivoDNG-mediated MK down-regulation observed here. However, it is
not clear whether this additional mode of action provides a more effect-
ive treatment of endometriosis. A recent study showed that DNG was
not associated with a statistically signiﬁcant improvement in overall
pain relief, psychological status, sexual functioning, or health-related
quality of life if compared with NETA treatment (Vercellini et al.,
Figure 1 Peritoneal ﬂuid (PF) midkine concentrations in the three
groups of patients. Midkine (MK) concentrations in women with non-
treated endometriosis (non- Dienogest (DNG) group; n ¼ 103) were
signiﬁcantly higher than those in women without endometriosis
(non-endometriosis group; n ¼ 88). DNG treatment (DNG group;
n ¼ 62) suppressed PF MK concentrations to levels even below
those observed in women without endometriosis (*P, 0.05,
****P, 0.0001). Boxes represent the median with 25th and 75th per-
centiles, the whiskers the minimum and the maximum. The dotted
line represents the detection limit of the assay.
Figure2 Midkine (MK)mRNAproduction (%of control) in cultured primary endometrial stromal cells (ESC;Mean + sem, n ¼ 6) isolated fromwomen
with endometriosis. (A)Dienogest (DNG) treatmentof primary ESC signiﬁcantly suppressedMKproductionafter 6 hof incubation (*P, 0.05). In contrast
both (B) medroxyprogesterone acetate (MPA) and (C) norethisterone acetate (NETA) non-signiﬁcantly increased the production of MK mRNA.
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2016). Moreover, it cannot be excluded thatNETA andMPA could have
also down-regulated MK in vivo. This could be possible through a mech-
anism of action other than the suppression of MKmRNA production by
ESCobservedwithDNG.However, this was impossible to be evaluated
in the current study since noneof the patientswas taking anyof these two
progestins.
In the present study, both rAFS stage andpatient age varied signiﬁcant-
ly between the three groups of patients. A more advanced rAFS stage in
the women using DNG is not surprising, given that these women are
more likely to have suffered from severe pain and thus more likely to
be prescribed a medical treatment. It would be expected that this in-
crease in rAFS stage should be associatedwith an increase in theMKcon-
centration, whereas due to the effect of DNG the opposite is observed.
Women in theDNGgrouparealso signiﬁcantly younger than those in the
other groups. However, it is unlikely that this could have inﬂuenced the
results since in this case the highestMK concentrations would have been
expected in the non-endometriosis group that actually includes the
oldest patients. The main limitation of the current study, however, is
its non-randomised design. On the other hand, MK concentrations
were measured and documented prospectively with the laboratory
assistants being blinded on clinical and surgical patient information.
In summary, the present study demonstrates for the ﬁrst time a
DNG-mediated in vivo and in vitroMKdown-regulation in endometriosis.
This effect could contribute to both the reduction of endometriotic
lesion size and pain relief observed in patients with endometriosis after
treatment with DNG.
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